Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Tokio Marine Asset Management Co. Ltd.

Key Points

• Tokio Marine Asset Management Co. Ltd. increased its holdings in Regeneron Pharmaceuticals by 22.9%, acquiring an additional 2,805 shares during the 1st quarter, now owning 15,062 shares valued at approximately $9.55 million.
• Regeneron Pharmaceuticals reported a quarterly earnings per share of $12.89, significantly exceeding analyst expectations of $8.43, and an annual revenue increase of 3.6%.
• The company announced a quarterly dividend of $0.88 per share, yielding 0.6%, with dividends scheduled to be paid on September 3rd.

Tokio Marine Asset Management Co. Ltd. grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 22.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,062 shares of the biopharmaceutical company's stock after acquiring an additional 2,805 shares during the period. Tokio Marine Asset Management Co. Ltd.'s holdings in Regeneron Pharmaceuticals were worth $9,553,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. S Bank Fund Management Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth about $658,000. National Pension Service increased its stake in shares of Regeneron Pharmaceuticals by 8.9% during the first quarter. National Pension Service now owns 253,046 shares of the biopharmaceutical company's stock worth $160,489,000 after purchasing an additional 20,596 shares in the last quarter. LGT Fund Management Co Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 17.5% during the first quarter. LGT Fund Management Co Ltd. now owns 658 shares of the biopharmaceutical company's stock worth $417,000 after purchasing an additional 98 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 6.9% during the first quarter. Russell Investments Group Ltd. now owns 146,740 shares of the biopharmaceutical company's stock worth $93,079,000 after purchasing an additional 9,532 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. increased its stake in shares of Regeneron Pharmaceuticals by 3.3% during the first quarter. Resona Asset Management Co. Ltd. now owns 38,436 shares of the biopharmaceutical company's stock worth $24,393,000 after purchasing an additional 1,225 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.8%

Shares of Regeneron Pharmaceuticals stock traded up $4.42 during mid-day trading on Thursday, hitting $565.97. The stock had a trading volume of 975,056 shares, compared to its average volume of 986,507. The firm has a 50-day moving average of $542.46 and a two-hundred day moving average of $596.26. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. The firm has a market cap of $59.99 billion, a P/E ratio of 14.26, a price-to-earnings-growth ratio of 1.90 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the prior year, the company posted $11.56 EPS. The business's revenue for the quarter was up 3.6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on REGN shares. Morgan Stanley reissued an "overweight" rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Finally, Royal Bank Of Canada boosted their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a research note on Monday, August 4th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $838.00.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.